Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers

Commercial payers that ultimately decide to cover aducanumab or other Alzheimer’s disease therapies may require innovative payment tools to minimize their financial risk given the uncertain benefits and high cost of such treatments. Drawing on the published evidence, we propose two different types o...

Full description

Saved in:
Bibliographic Details
Published in:PharmacoEconomics 2022-07, Vol.40 (7), p.647-652
Main Authors: Hlávka, Jakub P., Lavelle, Tara A., Neumann, Peter J., Lin, Pei-Jung
Format: Article
Language:English
Subjects:
Alzheimer Disease - drug therapy
Alzheimer's disease
Bias
Clinical outcomes
Clinical trials
Cognitive ability
Costs
Current Opinion
Drug therapy
FDA approval
Health Administration
Health Economics
Humans
Infrastructure
Installment payments
Management
Medicaid
Medicare
Medicine
Medicine & Public Health
Patients
Pharmacoeconomics and Health Outcomes
Prospective payment systems (Medical care)
Public Health
Quality of Life Research
Social aspects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c542t-e525f917b9fdf696afdf644054383584380def874331d97eaf58f99bc41812c83
cites cdi_FETCH-LOGICAL-c542t-e525f917b9fdf696afdf644054383584380def874331d97eaf58f99bc41812c83
container_end_page 652
container_issue 7
container_start_page 647
container_title PharmacoEconomics
container_volume 40
creator Hlávka, Jakub P.
Lavelle, Tara A.
Neumann, Peter J.
Lin, Pei-Jung
description Commercial payers that ultimately decide to cover aducanumab or other Alzheimer’s disease therapies may require innovative payment tools to minimize their financial risk given the uncertain benefits and high cost of such treatments. Drawing on the published evidence, we propose two different types of payment models applicable to disease-modifying therapies in Alzheimer’s disease, and suggest four strategies to overcome challenges in their implementation. Such strategies range from developing best practices for outcome measurement in Alzheimer’s disease, investing in infrastructure to collect real-world data, increasing representativeness of registry data in Alzheimer’s disease, and integrating the diagnostic, treatment, and payment landscape. These important steps could make access to emerging therapies in Alzheimer’s disease more sustainable in the long term, and could serve as a blueprint for better access to novel therapies in other indications in the future.
doi_str_mv 10.1007/s40273-022-01150-w
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10372750</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714271105</galeid><sourcerecordid>A714271105</sourcerecordid><originalsourceid>FETCH-LOGICAL-c542t-e525f917b9fdf696afdf644054383584380def874331d97eaf58f99bc41812c83</originalsourceid><addsrcrecordid>eNp9kttu1DAQhiMEogd4AS6QJW64SfExjq_QastJKlCJ9tryJuNdV0682NmuylVfg9frk9RpSktRhSx5LM83_2hGf1G8IviAYCzfJY6pZCWmtMSECFxunxS7hEhV0px4evPGpawU3in2UjrDGFdM0ufFDhNCMEzVbjHM2jZCSq5fovnKeA_9EhIaApr5AWJvBncO6NhcdNAP6GtowSdkQ0TfYJuRXytwHcSry98JHboEJgE6WUE0awcTd_oDzUOXmcYZPwpBTC-KZ9b4BC9v435x-vHDyfxzefT905f57KhsBKdDCYIKq4hcKNvaSlVmDJxjwVnNRJ1v3IKtJWeMtEqCsaK2Si0aTmpCm5rtF-8n3fVm0UHb5BGi8XodXWfihQ7G6YeZ3q30MpxrgvOepMBZ4e2tQgw_N5AG3bnUgPemh7BJmlYVl4oqNjZ78w96FjZ5gX6kallTySt5Ty2NB-16G3LjZhTVM0k4lYRgkamDR6h8WuhcE3qwLv8_KKBTQRNDShHs3ZAE69EsejKLzmbRN2bR21z0-u_13JX8cUcG2ASknMq-iPcj_Uf2Gk-vyug</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2687827467</pqid></control><display><type>article</type><title>Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers</title><source>Nexis UK</source><source>ABI/INFORM Global</source><source>Springer Nature</source><creator>Hlávka, Jakub P. ; Lavelle, Tara A. ; Neumann, Peter J. ; Lin, Pei-Jung</creator><creatorcontrib>Hlávka, Jakub P. ; Lavelle, Tara A. ; Neumann, Peter J. ; Lin, Pei-Jung</creatorcontrib><description>Commercial payers that ultimately decide to cover aducanumab or other Alzheimer’s disease therapies may require innovative payment tools to minimize their financial risk given the uncertain benefits and high cost of such treatments. Drawing on the published evidence, we propose two different types of payment models applicable to disease-modifying therapies in Alzheimer’s disease, and suggest four strategies to overcome challenges in their implementation. Such strategies range from developing best practices for outcome measurement in Alzheimer’s disease, investing in infrastructure to collect real-world data, increasing representativeness of registry data in Alzheimer’s disease, and integrating the diagnostic, treatment, and payment landscape. These important steps could make access to emerging therapies in Alzheimer’s disease more sustainable in the long term, and could serve as a blueprint for better access to novel therapies in other indications in the future.</description><identifier>ISSN: 1170-7690</identifier><identifier>EISSN: 1179-2027</identifier><identifier>DOI: 10.1007/s40273-022-01150-w</identifier><identifier>PMID: 35553029</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer's disease ; Bias ; Clinical outcomes ; Clinical trials ; Cognitive ability ; Costs ; Current Opinion ; Drug therapy ; FDA approval ; Health Administration ; Health Economics ; Humans ; Infrastructure ; Installment payments ; Management ; Medicaid ; Medicare ; Medicine ; Medicine &amp; Public Health ; Patients ; Pharmacoeconomics and Health Outcomes ; Prospective payment systems (Medical care) ; Public Health ; Quality of Life Research ; Social aspects</subject><ispartof>PharmacoEconomics, 2022-07, Vol.40 (7), p.647-652</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><rights>COPYRIGHT 2022 Springer</rights><rights>Copyright Springer Nature B.V. Jul 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c542t-e525f917b9fdf696afdf644054383584380def874331d97eaf58f99bc41812c83</citedby><cites>FETCH-LOGICAL-c542t-e525f917b9fdf696afdf644054383584380def874331d97eaf58f99bc41812c83</cites><orcidid>0000-0002-2766-390X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2687827467/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2687827467?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,776,780,881,11668,27903,27904,36039,36040,44342,74641</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35553029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hlávka, Jakub P.</creatorcontrib><creatorcontrib>Lavelle, Tara A.</creatorcontrib><creatorcontrib>Neumann, Peter J.</creatorcontrib><creatorcontrib>Lin, Pei-Jung</creatorcontrib><title>Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers</title><title>PharmacoEconomics</title><addtitle>PharmacoEconomics</addtitle><addtitle>Pharmacoeconomics</addtitle><description>Commercial payers that ultimately decide to cover aducanumab or other Alzheimer’s disease therapies may require innovative payment tools to minimize their financial risk given the uncertain benefits and high cost of such treatments. Drawing on the published evidence, we propose two different types of payment models applicable to disease-modifying therapies in Alzheimer’s disease, and suggest four strategies to overcome challenges in their implementation. Such strategies range from developing best practices for outcome measurement in Alzheimer’s disease, investing in infrastructure to collect real-world data, increasing representativeness of registry data in Alzheimer’s disease, and integrating the diagnostic, treatment, and payment landscape. These important steps could make access to emerging therapies in Alzheimer’s disease more sustainable in the long term, and could serve as a blueprint for better access to novel therapies in other indications in the future.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer's disease</subject><subject>Bias</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>Cognitive ability</subject><subject>Costs</subject><subject>Current Opinion</subject><subject>Drug therapy</subject><subject>FDA approval</subject><subject>Health Administration</subject><subject>Health Economics</subject><subject>Humans</subject><subject>Infrastructure</subject><subject>Installment payments</subject><subject>Management</subject><subject>Medicaid</subject><subject>Medicare</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Patients</subject><subject>Pharmacoeconomics and Health Outcomes</subject><subject>Prospective payment systems (Medical care)</subject><subject>Public Health</subject><subject>Quality of Life Research</subject><subject>Social aspects</subject><issn>1170-7690</issn><issn>1179-2027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>M0C</sourceid><recordid>eNp9kttu1DAQhiMEogd4AS6QJW64SfExjq_QastJKlCJ9tryJuNdV0682NmuylVfg9frk9RpSktRhSx5LM83_2hGf1G8IviAYCzfJY6pZCWmtMSECFxunxS7hEhV0px4evPGpawU3in2UjrDGFdM0ufFDhNCMEzVbjHM2jZCSq5fovnKeA_9EhIaApr5AWJvBncO6NhcdNAP6GtowSdkQ0TfYJuRXytwHcSry98JHboEJgE6WUE0awcTd_oDzUOXmcYZPwpBTC-KZ9b4BC9v435x-vHDyfxzefT905f57KhsBKdDCYIKq4hcKNvaSlVmDJxjwVnNRJ1v3IKtJWeMtEqCsaK2Si0aTmpCm5rtF-8n3fVm0UHb5BGi8XodXWfihQ7G6YeZ3q30MpxrgvOepMBZ4e2tQgw_N5AG3bnUgPemh7BJmlYVl4oqNjZ78w96FjZ5gX6kallTySt5Ty2NB-16G3LjZhTVM0k4lYRgkamDR6h8WuhcE3qwLv8_KKBTQRNDShHs3ZAE69EsejKLzmbRN2bR21z0-u_13JX8cUcG2ASknMq-iPcj_Uf2Gk-vyug</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Hlávka, Jakub P.</creator><creator>Lavelle, Tara A.</creator><creator>Neumann, Peter J.</creator><creator>Lin, Pei-Jung</creator><general>Springer International Publishing</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>4T-</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2766-390X</orcidid></search><sort><creationdate>20220701</creationdate><title>Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers</title><author>Hlávka, Jakub P. ; Lavelle, Tara A. ; Neumann, Peter J. ; Lin, Pei-Jung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c542t-e525f917b9fdf696afdf644054383584380def874331d97eaf58f99bc41812c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer's disease</topic><topic>Bias</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>Cognitive ability</topic><topic>Costs</topic><topic>Current Opinion</topic><topic>Drug therapy</topic><topic>FDA approval</topic><topic>Health Administration</topic><topic>Health Economics</topic><topic>Humans</topic><topic>Infrastructure</topic><topic>Installment payments</topic><topic>Management</topic><topic>Medicaid</topic><topic>Medicare</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Patients</topic><topic>Pharmacoeconomics and Health Outcomes</topic><topic>Prospective payment systems (Medical care)</topic><topic>Public Health</topic><topic>Quality of Life Research</topic><topic>Social aspects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hlávka, Jakub P.</creatorcontrib><creatorcontrib>Lavelle, Tara A.</creatorcontrib><creatorcontrib>Neumann, Peter J.</creatorcontrib><creatorcontrib>Lin, Pei-Jung</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM Global</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>One Business (ProQuest)</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>PharmacoEconomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hlávka, Jakub P.</au><au>Lavelle, Tara A.</au><au>Neumann, Peter J.</au><au>Lin, Pei-Jung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers</atitle><jtitle>PharmacoEconomics</jtitle><stitle>PharmacoEconomics</stitle><addtitle>Pharmacoeconomics</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>40</volume><issue>7</issue><spage>647</spage><epage>652</epage><pages>647-652</pages><issn>1170-7690</issn><eissn>1179-2027</eissn><abstract>Commercial payers that ultimately decide to cover aducanumab or other Alzheimer’s disease therapies may require innovative payment tools to minimize their financial risk given the uncertain benefits and high cost of such treatments. Drawing on the published evidence, we propose two different types of payment models applicable to disease-modifying therapies in Alzheimer’s disease, and suggest four strategies to overcome challenges in their implementation. Such strategies range from developing best practices for outcome measurement in Alzheimer’s disease, investing in infrastructure to collect real-world data, increasing representativeness of registry data in Alzheimer’s disease, and integrating the diagnostic, treatment, and payment landscape. These important steps could make access to emerging therapies in Alzheimer’s disease more sustainable in the long term, and could serve as a blueprint for better access to novel therapies in other indications in the future.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>35553029</pmid><doi>10.1007/s40273-022-01150-w</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-2766-390X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1170-7690
ispartof PharmacoEconomics, 2022-07, Vol.40 (7), p.647-652
issn 1170-7690
1179-2027
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10372750
source Nexis UK; ABI/INFORM Global; Springer Nature
subjects Alzheimer Disease - drug therapy
Alzheimer's disease
Bias
Clinical outcomes
Clinical trials
Cognitive ability
Costs
Current Opinion
Drug therapy
FDA approval
Health Administration
Health Economics
Humans
Infrastructure
Installment payments
Management
Medicaid
Medicare
Medicine
Medicine & Public Health
Patients
Pharmacoeconomics and Health Outcomes
Prospective payment systems (Medical care)
Public Health
Quality of Life Research
Social aspects
title Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T21%3A11%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Addressing%20Challenges%20to%20Alternative%20Payment%20Models%20for%20New%20Alzheimer%E2%80%99s%20Disease%20Therapies%20for%20US%20Commercial%20Payers&rft.jtitle=PharmacoEconomics&rft.au=Hl%C3%A1vka,%20Jakub%20P.&rft.date=2022-07-01&rft.volume=40&rft.issue=7&rft.spage=647&rft.epage=652&rft.pages=647-652&rft.issn=1170-7690&rft.eissn=1179-2027&rft_id=info:doi/10.1007/s40273-022-01150-w&rft_dat=%3Cgale_pubme%3EA714271105%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c542t-e525f917b9fdf696afdf644054383584380def874331d97eaf58f99bc41812c83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2687827467&rft_id=info:pmid/35553029&rft_galeid=A714271105&rfr_iscdi=true